Year in Review
Year ended March 2023
Key Figures
- Net Sales
- ¥1,062.1billion
- 4.8%
- Operating Income
- ¥75.4billion
- 18.8%
- Operating Income Ratio
- 7.1%
- 2.1percentage points
- ROE
- 10.0%
- 3.5percentage points
- Capital Expenditures
- ¥72.1billion
- R&D Expenses
- ¥30.9billion
Breakdown by Segment
- Food
- Pharmaceuticals
Net Sales
Operating Income
Business Performance Analysis
Food
- Net Sales
- ¥865.6billion
- 4.8%
- Operating Income
- ¥55.8billion
- 26.5%
- Income Analysis(Billions of yen)
-
Pharmaceuticals
- Net Sales
- ¥197.2billion
- 4.9%
- Operating Income
- ¥21.7billion
- 16.4%
- Income Analysis(Billions of yen)
-
Capital Expenditures
- Food
- Pharmaceuticals
Food
¥63.4billion
Pharmaceuticals
¥8.5billion
Cash Dividends per Share / Dividend Payout Ratio
- Cash Dividends per Share
Dividend Payout Ratio
Future Prospects
This is our Medium-term Business Plan,
FYE 3/2022 through FYE 3/2024.
| FYE3/2022 Results |
FYE3/2023 Results |
FYE3/2024 Plan |
FYE3/2024 Targets (Initial plan) |
||
|---|---|---|---|---|---|
| Net sales | ¥1,013.0 biliion | ¥1,062.1 biliion | ¥1,102.0 biliion | ¥1,080.0 biliion | |
| Operating income | ¥92.9 billion | ¥75.4 billion | ¥78.0 billion | ¥120.0 billion | |
| Operating income ratio | 9.2% | 7.1% | 7.1% | 11.1% | |
| ROE | 13.5% | 10.0% | 7.0% | 11.0% | |
| as of May 11, 2023 | as of May 18, 2021 |